Cargando…

Defective Severe Acute Respiratory Syndrome Coronavirus 2 Immune Responses in an Immunocompromised Individual With Prolonged Viral Replication

We describe severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–specific immune responses in a patient with lymphoma and recent programmed death 1 (PD-1) inhibitor therapy with late onset of severe coronavirus disease 2019 disease and prolonged SARS-CoV-2 replication, in comparison to age-m...

Descripción completa

Detalles Bibliográficos
Autores principales: Gordon, Claire L, Smibert, Olivia C, Holmes, Natasha E, Chua, Kyra Y L, Rose, Morgan, Drewett, George, James, Fiona, Mouhtouris, Effie, Nguyen, Thi H O, Zhang, Wuji, Kedzierski, Lukasz, Rowntree, Louise C, Chua, Brendon Y, Caly, Leon, Catton, Mike G, Druce, Julian, Sait, Michelle, Seemann, Torsten, Sherry, Norelle L, Howden, Benjamin P, Kedzierska, Katherine, Kwong, Jason C, Trubiano, Jason A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419740/
https://www.ncbi.nlm.nih.gov/pubmed/34514016
http://dx.doi.org/10.1093/ofid/ofab359
Descripción
Sumario:We describe severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–specific immune responses in a patient with lymphoma and recent programmed death 1 (PD-1) inhibitor therapy with late onset of severe coronavirus disease 2019 disease and prolonged SARS-CoV-2 replication, in comparison to age-matched and immunocompromised controls. High levels of HLA-DR(+)/CD38(+) activation, interleukin 6, and interleukin 18 in the absence of B cells and PD-1 expression was observed. SARS-CoV-2–specific antibody responses were absent and SARS-CoV-2–specific T cells were minimally detected. This case highlights challenges in managing immunocompromised hosts who may fail to mount effective virus-specific immune responses.